What Makes Tremfya Unique Among IL-23 Inhibitors?
Tremfya (guselkumab) targets only the p19 subunit of IL-23, blocking the cytokine more selectively than other IL-23 inhibitors like Skyrizi (risankizumab) or Cosentyx (secukinumab), which also hit p19 but differ in binding affinity and pharmacokinetics. This selectivity reduces off-target effects on unrelated cytokines. Tremfya is approved for plaque psoriasis, psoriatic arthritis, and Crohn's disease, with dosing every 8 weeks after initial loads via subcutaneous injection.[1]
How Do Dosing Schedules Compare?
Tremfya requires two 100 mg subcutaneous doses (weeks 0 and 4), then every 8 weeks—less frequent than Skyrizi's every 12 weeks or Ilumya's (tildrakizumab) every 12 weeks after two doses. Cosentyx, an IL-17A inhibitor often grouped in comparisons, needs weekly loading then monthly. Fewer injections with Tremfya improve patient adherence in long-term studies.[2]
Efficacy Head-to-Head: Psoriasis and Beyond
In psoriasis trials, Tremfya achieved 73-85% PASI 90 response at week 16, matching Skyrizi's 75-80% but outperforming older IL-12/23 inhibitors like Stelara (ustekinumab, 40-50%). For psoriatic arthritis, Tremfya shows ACR20 rates of 59-70% at week 24; Skyrizi hits similar marks but lacks Crohn's approval, where Tremfya reaches clinical remission in 47% of patients by week 12. Direct comparator trials are limited, but network meta-analyses rank Tremfya and Skyrizi as top-tier for skin clearance.[3]
Safety Profile Differences
All share risks like infections and rare hypersensitivity, but Tremfya's p19-only targeting correlates with lower rates of serious infections (4-6%) versus Stelara's broader IL-12/23 block (up to 8%). Skyrizi reports similar mild adverse events (headache, fatigue), with no major differentiators in post-marketing data. Long-term Tremfya data (5+ years) show sustained safety without new signals.[1][4]
Who's Behind Tremfya and When Do Patents Expire?
Janssen (Johnson & Johnson) developed and markets Tremfya, approved by FDA in 2017. Key patents cover the antibody sequence and formulations, expiring around 2032-2033 in the US, per DrugPatentWatch; biosimilars could challenge earlier via litigation, as seen with Skyrizi patent disputes.[5]
Cost and Access Compared
Tremfya's wholesale price is about $6,500 per 100 mg dose (every 8 weeks), similar to Skyrizi's $6,000-7,000 but higher than Ilumya's ~$5,500. Patient assistance programs and buy-and-bill models level access, though payer preferences favor Tremfya for multi-indication use.[6]
Sources
[1]: FDA Tremfya Label
[2]: Janssen Clinical Data
[3]: Network Meta-Analysis, Lancet 2020
[4]: Safety Review, J Am Acad Dermatol 2022
[5]: DrugPatentWatch: Guselkumab Patents
[6]: Drugs.com Price Guide